1
|
Morace I, Pilz R, Federico G, Jennemann R, Krunic D, Nordström V, von Gerichten J, Marsching C, Schießl IM, Müthing J, Wunder C, Johannes L, Sandhoff R, Gröne HJ. Renal globotriaosylceramide facilitates tubular albumin absorption and its inhibition protects against acute kidney injury. Kidney Int 2019; 96:327-341. [PMID: 31101366 DOI: 10.1016/j.kint.2019.02.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Revised: 02/01/2019] [Accepted: 02/07/2019] [Indexed: 11/29/2022]
Abstract
To elucidate the physiologic function of renal globotriaosylceramide (Gb3/CD77), which up-to-date has been associated exclusively with Shiga toxin binding, we have analyzed renal function in Gb3-deficient mice. Gb3 synthase KO (Gb3S-/-) mice displayed an increased renal albumin and low molecular weight protein excretion compared to WT. Gb3 localized at the brush border and within vesicular structures in WT proximal tubules and has now been shown to be closely associated with the receptor complex megalin/cubilin and with albumin uptake. In two clinically relevant mouse models of acute kidney injury caused by myoglobin as seen in rhabdomyolysis and the aminoglycoside gentamicin, Gb3S-/- mice showed a preserved renal function and morphology, compared to WT. Pharmacologic inhibition of glucosylceramide-based glycosphingolipids, including Gb3, in WT mice corroborated the results of genetically Gb3-deficient mice. In conclusion, our data significantly advance the current knowledge on the physiologic and pathophysiologic role of Gb3 in proximal tubules, showing an involvement in the reabsorption of filtered albumin, myoglobin and the aminoglycoside gentamicin.
Collapse
Affiliation(s)
- Ivan Morace
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany.
| | - Robert Pilz
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany; Lipid Pathobiochemistry Group, German Cancer Research Center, Heidelberg, Germany
| | - Giuseppina Federico
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany
| | - Richard Jennemann
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany
| | - Damir Krunic
- Light Microscopy Facility, German Cancer Research Center, Heidelberg, Germany
| | - Viola Nordström
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany
| | - Johanna von Gerichten
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany; Lipid Pathobiochemistry Group, German Cancer Research Center, Heidelberg, Germany
| | - Christian Marsching
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany; Lipid Pathobiochemistry Group, German Cancer Research Center, Heidelberg, Germany
| | - Ina Maria Schießl
- Institute of Physiology, University of Regensburg, Regensburg, Germany
| | | | - Christian Wunder
- Institut Curie, PSL Research University, Chemical Biology of Membranes and Therapeutic Delivery Unit, CNRS UMR3666, INSERM U1143, Paris, France
| | - Ludger Johannes
- Institut Curie, PSL Research University, Chemical Biology of Membranes and Therapeutic Delivery Unit, CNRS UMR3666, INSERM U1143, Paris, France
| | - Roger Sandhoff
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany; Lipid Pathobiochemistry Group, German Cancer Research Center, Heidelberg, Germany
| | - Hermann-Josef Gröne
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany; Institute of Pharmacology, University of Marburg, Marburg, Germany.
| |
Collapse
|
2
|
von Gerichten J, Schlosser K, Lamprecht D, Morace I, Eckhardt M, Wachten D, Jennemann R, Gröne HJ, Mack M, Sandhoff R. Diastereomer-specific quantification of bioactive hexosylceramides from bacteria and mammals. J Lipid Res 2017; 58:1247-1258. [PMID: 28373486 DOI: 10.1194/jlr.d076190] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2017] [Revised: 03/30/2017] [Indexed: 12/19/2022] Open
Abstract
Mammals synthesize, cell-type specifically, the diastereomeric hexosylceramides, β-galactosylceramide (GalCer) and β-glucosylceramide (GlcCer), which are involved in several diseases, such as sphingolipidosis, diabetes, chronic kidney diseases, or cancer. In contrast, Bacteroides fragilis, a member of the human gut microbiome, and the marine sponge, Agelas mauritianus, produce α-GalCer, one of the most potent stimulators for invariant natural killer T cells. To dissect the contribution of these individual stereoisomers to pathologies, we established a novel hydrophilic interaction chromatography-based LC-MS2 method and separated (R > 1.5) corresponding diastereomers from each other, independent of their lipid anchors. Testing various bacterial and mammalian samples, we could separate, identify (including the lipid anchor composition), and quantify endogenous β-GlcCer, β-GalCer, and α-GalCer isomers without additional derivatization steps. Thereby, we show a selective decrease of β-GlcCers versus β-GalCers in cell-specific models of GlcCer synthase-deficiency and an increase of specific β-GlcCers due to loss of β-glucoceramidase 2 activity. Vice versa, β-GalCer increased specifically when cerebroside sulfotransferase (Gal3st1) was deleted. We further confirm β-GalCer as substrate of globotriaosylceramide synthase for galabiaosylceramide synthesis and identify additional members of the human gut microbiome to contain immunogenic α-GalCers. Finally, this method is shown to separate corresponding hexosylsphingosine standards, promoting its applicability in further investigations.
Collapse
Affiliation(s)
- Johanna von Gerichten
- Lipid Pathobiochemistry Group German Cancer Research Center, Heidelberg, Germany.,Instrumental Analytics and Bioanalytics, Mannheim University of Applied Sciences, Mannheim, Germany
| | - Kerstin Schlosser
- Department of Biotechnology, Institute for Technical Microbiology, Mannheim University of Applied Sciences, Mannheim, Germany
| | - Dominic Lamprecht
- Lipid Pathobiochemistry Group German Cancer Research Center, Heidelberg, Germany.,Center for Applied Research in Biomedical Mass Spectrometry (ABIMAS), Mannheim University of Applied Sciences, Mannheim, Germany
| | - Ivan Morace
- Department of Molecular and Cellular Pathology, German Cancer Research Center, Heidelberg, Germany
| | - Matthias Eckhardt
- Institute of Biochemistry and Molecular Biology and Center for Rare Diseases University of Bonn, Bonn, Germany
| | - Dagmar Wachten
- Minerva Max Planck Research Group, Molecular Physiology, Center of Advanced European Studies and Research, Bonn, Germany.,Institute of Innate Immunity, University Hospital, University of Bonn, Bonn, Germany
| | - Richard Jennemann
- Department of Molecular and Cellular Pathology, German Cancer Research Center, Heidelberg, Germany
| | - Hermann-Josef Gröne
- Department of Molecular and Cellular Pathology, German Cancer Research Center, Heidelberg, Germany
| | - Matthias Mack
- Department of Biotechnology, Institute for Technical Microbiology, Mannheim University of Applied Sciences, Mannheim, Germany
| | - Roger Sandhoff
- Lipid Pathobiochemistry Group German Cancer Research Center, Heidelberg, Germany .,Center for Applied Research in Biomedical Mass Spectrometry (ABIMAS), Mannheim University of Applied Sciences, Mannheim, Germany
| |
Collapse
|